HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis

Suhayl Dhib-Jalbut, Reuben M. Valenzuela, Kouichi Ito, Michael Kaufman, Mary Ann Picone, Steven Buyske

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: Clinical response to immunomodulatory therapies in multiple sclerosis (MS) is variable among patients. Currently, there are no validated biomarkers of clinical response to any of the approved treatments for MS. The objective of this study was to determine if HLA-class II alleles predict the clinical response to glatiramer acetate (GA). Methods: This was a prospective study of 64 MS patients with relapsing-remitting disease. Patients were HLA-typed and classified as GA-responders or non-responders after 2 years of treatment based on a clinical criterion. Statistical models were used to determine whether HLA-DR and DQ alleles and haplotypes predict the clinical response to GA. Results: Tests of association of response singled out four alleles and two haplotypes with nominal p<0.01. The presence of alleles DR15 or DQ6 or the absence of DR17 and DQ2 alleles was associated with favorable clinical response. The presence of the DR15-DQ6 haplotype and the absence of the DR17-DQ2 haplotype were also associated with favorable treatment response. A best fitting two-haplotype model resulted in the identification of three prognostic categories (good, neutral, and poor). A DR15-DQ6 positive but DR17-DQ2 negative combination was strongly predictive of a favorable clinical response (71%). Conversely, a DR15-DQ6 negative but DR17-DQ2 positive combination was strongly predictive of poor clinical response to GA (17%). Conclusion: HLA-DR and DQ typing may prove to be useful biomarkers of predicting response to GA in MS and may help select patients appropriate for this treatment.

Original languageEnglish (US)
Pages (from-to)340-348
Number of pages9
JournalMultiple Sclerosis and Related Disorders
Volume2
Issue number4
DOIs
StatePublished - Oct 1 2013

Fingerprint

HLA-DQ Antigens
HLA-DR Antigens
Haplotypes
Multiple Sclerosis
Alleles
Biomarkers
Immunomodulation
Statistical Models
Therapeutics
Glatiramer Acetate
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

Cite this

@article{97013ae57c254049b16a46b4ff8a7860,
title = "HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis",
abstract = "Objective: Clinical response to immunomodulatory therapies in multiple sclerosis (MS) is variable among patients. Currently, there are no validated biomarkers of clinical response to any of the approved treatments for MS. The objective of this study was to determine if HLA-class II alleles predict the clinical response to glatiramer acetate (GA). Methods: This was a prospective study of 64 MS patients with relapsing-remitting disease. Patients were HLA-typed and classified as GA-responders or non-responders after 2 years of treatment based on a clinical criterion. Statistical models were used to determine whether HLA-DR and DQ alleles and haplotypes predict the clinical response to GA. Results: Tests of association of response singled out four alleles and two haplotypes with nominal p<0.01. The presence of alleles DR15 or DQ6 or the absence of DR17 and DQ2 alleles was associated with favorable clinical response. The presence of the DR15-DQ6 haplotype and the absence of the DR17-DQ2 haplotype were also associated with favorable treatment response. A best fitting two-haplotype model resulted in the identification of three prognostic categories (good, neutral, and poor). A DR15-DQ6 positive but DR17-DQ2 negative combination was strongly predictive of a favorable clinical response (71{\%}). Conversely, a DR15-DQ6 negative but DR17-DQ2 positive combination was strongly predictive of poor clinical response to GA (17{\%}). Conclusion: HLA-DR and DQ typing may prove to be useful biomarkers of predicting response to GA in MS and may help select patients appropriate for this treatment.",
author = "Suhayl Dhib-Jalbut and Valenzuela, {Reuben M.} and Kouichi Ito and Michael Kaufman and {Ann Picone}, Mary and Steven Buyske",
year = "2013",
month = "10",
day = "1",
doi = "10.1016/j.msard.2013.02.005",
language = "English (US)",
volume = "2",
pages = "340--348",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",
number = "4",

}

HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis. / Dhib-Jalbut, Suhayl; Valenzuela, Reuben M.; Ito, Kouichi; Kaufman, Michael; Ann Picone, Mary; Buyske, Steven.

In: Multiple Sclerosis and Related Disorders, Vol. 2, No. 4, 01.10.2013, p. 340-348.

Research output: Contribution to journalArticle

TY - JOUR

T1 - HLA DR and DQ alleles and haplotypes associated with clinical response to glatiramer acetate in multiple sclerosis

AU - Dhib-Jalbut, Suhayl

AU - Valenzuela, Reuben M.

AU - Ito, Kouichi

AU - Kaufman, Michael

AU - Ann Picone, Mary

AU - Buyske, Steven

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Objective: Clinical response to immunomodulatory therapies in multiple sclerosis (MS) is variable among patients. Currently, there are no validated biomarkers of clinical response to any of the approved treatments for MS. The objective of this study was to determine if HLA-class II alleles predict the clinical response to glatiramer acetate (GA). Methods: This was a prospective study of 64 MS patients with relapsing-remitting disease. Patients were HLA-typed and classified as GA-responders or non-responders after 2 years of treatment based on a clinical criterion. Statistical models were used to determine whether HLA-DR and DQ alleles and haplotypes predict the clinical response to GA. Results: Tests of association of response singled out four alleles and two haplotypes with nominal p<0.01. The presence of alleles DR15 or DQ6 or the absence of DR17 and DQ2 alleles was associated with favorable clinical response. The presence of the DR15-DQ6 haplotype and the absence of the DR17-DQ2 haplotype were also associated with favorable treatment response. A best fitting two-haplotype model resulted in the identification of three prognostic categories (good, neutral, and poor). A DR15-DQ6 positive but DR17-DQ2 negative combination was strongly predictive of a favorable clinical response (71%). Conversely, a DR15-DQ6 negative but DR17-DQ2 positive combination was strongly predictive of poor clinical response to GA (17%). Conclusion: HLA-DR and DQ typing may prove to be useful biomarkers of predicting response to GA in MS and may help select patients appropriate for this treatment.

AB - Objective: Clinical response to immunomodulatory therapies in multiple sclerosis (MS) is variable among patients. Currently, there are no validated biomarkers of clinical response to any of the approved treatments for MS. The objective of this study was to determine if HLA-class II alleles predict the clinical response to glatiramer acetate (GA). Methods: This was a prospective study of 64 MS patients with relapsing-remitting disease. Patients were HLA-typed and classified as GA-responders or non-responders after 2 years of treatment based on a clinical criterion. Statistical models were used to determine whether HLA-DR and DQ alleles and haplotypes predict the clinical response to GA. Results: Tests of association of response singled out four alleles and two haplotypes with nominal p<0.01. The presence of alleles DR15 or DQ6 or the absence of DR17 and DQ2 alleles was associated with favorable clinical response. The presence of the DR15-DQ6 haplotype and the absence of the DR17-DQ2 haplotype were also associated with favorable treatment response. A best fitting two-haplotype model resulted in the identification of three prognostic categories (good, neutral, and poor). A DR15-DQ6 positive but DR17-DQ2 negative combination was strongly predictive of a favorable clinical response (71%). Conversely, a DR15-DQ6 negative but DR17-DQ2 positive combination was strongly predictive of poor clinical response to GA (17%). Conclusion: HLA-DR and DQ typing may prove to be useful biomarkers of predicting response to GA in MS and may help select patients appropriate for this treatment.

UR - http://www.scopus.com/inward/record.url?scp=84880133942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880133942&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2013.02.005

DO - 10.1016/j.msard.2013.02.005

M3 - Article

VL - 2

SP - 340

EP - 348

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

IS - 4

ER -